Drug-Drug Interactions With Endocrine Therapy in BC Patients
Endocrine therapy reduces recurrence and mortality rates in breast cancer (BC) patients with estrogen-positive/progesterone-positive disease. Adherence to endocrine therapy is essential to achieve maximal benefit. Numerous factors can play a role in contributing to medication nonadherence, among which can be the concern over drug-drug interactions; however, little is known as to whether this concern affects adherence to endocrine therapy in BC patients. Read more.

Overall Survival With Palbociclib, Aromatase Inhibitors in Metastatic BC
Among those recently diagnosed with breast cancer (BC), approximately 6% of cases have already metastasized, resulting in a 5-year survival rate of 29.0%. Recommended treatment options include the use of cyclin-dependent kinase 4/6-inibitors in combination with endocrine therapy. Learn more about results of a study that compared overall survival of patients with metastatic BC and palbociclib/aromatase inhibitor use.

Adverse Effects of PD-1, PD-L1 Inhibitors in TNBC
The advent of the PD (programmed cell death)-1 and PD-L1 (programmed cell death ligand) inhibitors, two classes of immune checkpoint inhibitors, opened a new avenue of treatment for patients with triple-negative breast cancer (TNBC). This population accounts for approximately 10% to 20% of all breast cancer cases and is associated with greater than 40% mortality rate within the first 5 years. Read more.